Pain Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Single-dose, Multiple-dose,Dose-escalated Phase I Clinical Study Trial to Evaluate the Tolerance and Pharmacokinetics of Felbinac Trometamol Injection in Healthy Subjects
Verified date | July 2020 |
Source | Shijiazhuang Yiling Pharmaceutical Co. Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
1. To evaluate the tolerances of healthy subjects treated with Felbinac Trometamol
Injection on multiple dose and single dose
2. To evaluate the pharmacokinetic characteristics in healthy subjects treated with
Felbinac Trometamol Injection on multiple dose and single dose
3. To provide the basis for the dose for the follow-up clinical study.
Status | Completed |
Enrollment | 48 |
Est. completion date | April 30, 2019 |
Est. primary completion date | November 5, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Sign the informed consent form before the trial and fully understand the contents of the trial, the process and possible adverse reactions; 2. Be able to complete the research according to the clinical trial protocol; 3. Subjects have no pregnancy plan within the next 6 months and voluntarily take effective contraceptive measures; 4. Male and female subjects between 18 and 45 years (inclusive) of age; 5. Male subjects weighing no less than 50 kg, female subjects weighing no less than 45 kg.Body Mass Index (BMI) 18 to 28 kg/m2 (inclusive); 6. Physical examination, vital signs normal or no clinical significance. Exclusion Criteria: 1. Someone smoking more than 5 pieces per day within the 3 months before the trial ; 2. Allergies, such as allergies to two or more drugs, food and pollen, or known to the drug component or ethylbenzene ethyl acetate allergy; 3. Having a history of drug and / or alcohol abuse (14 units of alcohol per week: 1 units = beer 285 mL, or 25 mL of spirits, or 100 mL of wine); 4. Blood donation or extensive blood loss (> 400 mL) within three months of the use of the study drug; 5. Taked any drug that changes liver enzyme activity 28 days prior to the use of the study drug; 6. Taked any prescription, OTC drugs, any vitamin products or herbs within 14 days prior to the use of the study drug; 7. Two weeks before the trial took a special diet (including dragon fruit, mango, grapefruit, and / or rich in xanthine diet, etc.) or strenuous exercise, and other avtivites that affect drug absorption, distribution, metabolism, excretion and so on; 8. Combined with the following CYP3A4, p-gp or Bcrp inhibitors or inducers, such as itraconazole, ketoconazole or dronedarone; 9. There have been significant changes in diet or exercise habits recently; 10. Taked research drugs within three months prior to the use of the study drug or participating in any drug clinical trial; 11. Suffering from any increased risk of hemorrhagic disease, such as hemorrhoids, acute gastritis or stomach and duodenal ulcers; 12. ECG has clinical significance; 13. Female subjects are in lactation or serum pregnancy test are positive during screening or during the test. 14. Clinical laboratory tests are abnormal and have clinical significance, or other clinical findings showing clinically significant diseases (including but not limited to gastrointestinal, renal, liver, nerves, blood, endocrine, neoplasms, lungs, immunizations, mental or heart Cerebrovascular disease); 15. hepatitis (including hepatitis B and hepatitis C), AIDS, syphilis screening test positive; 16. Acute disease occurs before screening or using test drug; 17. Taking chocolate, any caffeine, or xanthine-rich food or drink at least 48 hours prior to the use of the study drug; 18. Taking any alcoholic products within 24 hours prior to the use of the study drug; 19. Alcohol or drug screening positive or drug abuse history over the past five years or 3 months before the trial used by drug users. |
Country | Name | City | State |
---|---|---|---|
China | The First Hospital of Jilin University | Changchun | Jilin |
Lead Sponsor | Collaborator |
---|---|
Shijiazhuang Yiling Pharmaceutical Co. Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tolerance evaluation index | percent of subjects with adverse reactions | up to 96.5 hours after mutil-dose | |
Secondary | Tmax | The amount of time that a drug is present at the maximum concentration in serum. | up to 96.5 hours after mutil-dose | |
Secondary | Peak Plasma Concentration (Cmax) | The PK parameters of the plasma sample | up to 96.5 hours after mutil-dose | |
Secondary | t1/2 | The PK parameters of the plasma sample | up to 96.5 hours after mutil-dose | |
Secondary | Vd | The PK parameters of the plasma sample | up to 96.5 hours after mutil-dose | |
Secondary | Mean residence time (MRT) parameter. | The PK parameters of the plasma sample | up to 96.5 hours after mutil-dose | |
Secondary | Ke | The PK parameters of the plasma sample | up to 96.5 hours after mutil-dose | |
Secondary | Area under the plasma concentration versus time curve (AUC0-8) | The PK parameters of the plasma sample | up to 96.5 hours after mutil-dose | |
Secondary | AUC0-48 | The PK parameters of the plasma sample | up to 96.5 hours after mutil-dose | |
Secondary | Ae0-48 | The PK parameters of the urine and the stool sample | up to 96.5 hours after mutil-dose | |
Secondary | AUC0-last | The PK parameters of the plasma sample | up to 96.5 hours after mutil-dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05559255 -
Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI
|
N/A | |
Completed |
NCT04748367 -
Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care
|
N/A | |
Terminated |
NCT04356352 -
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
|
Phase 2/Phase 3 | |
Recruiting |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04466111 -
Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
|
||
Recruiting |
NCT05868122 -
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
|
Phase 3 | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Completed |
NCT03273114 -
Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain
|
N/A | |
Enrolling by invitation |
NCT06087432 -
Is PNF Application Effective on Temporomandibular Dysfunction
|
N/A | |
Completed |
NCT05508594 -
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001
|
Phase 2/Phase 3 | |
Recruiting |
NCT03646955 -
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03472300 -
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
|
||
Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
Completed |
NCT03286543 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System
|
N/A | |
Completed |
NCT02913027 -
Can We Improve the Comfort of Pelvic Exams?
|
N/A | |
Terminated |
NCT02181387 -
Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?
|
Phase 4 | |
Recruiting |
NCT06032559 -
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
|
Phase 3 | |
Active, not recruiting |
NCT03613155 -
Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care
|